RUXOLITINIB PHOSPHATEfirst possible commercially ready supplier
GMP SUPPLIER - US FDA APPROVAL - USDMF AVAILABLE
RUXOLITINIB PHOSPHATE (CAS 220127-57-1) is a Janus kinase inhibitor for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow. It is also approved for polycythemia vera and is being investigated for treatment of other kinds of cancer.
Originator product: JAKAFI® and JAKAVI®
- FDA-approved, WC available
- Active US DMF available
- GMP supplier
This article uses material from Wikipedia, which is released under the Creative Commons Attribution-Share-Alike License 3.0.